Table 1 Patient characteristics at baseline
|  | T790M negative (n = 33) | T790M positive (n = 30) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|  | With PE (n = 12) | Without PE (n = 21) | p-Value | With PE (n = 12) | Without PE (n = 18) | p-Value | ||||
Median age (range), years | 72 | (48–88) | 70 | (38–81) | 0.587 | 68.5 | (28–83) | 70 | (44–86) | 0.433 |
Gender, n (%) | ||||||||||
 Male | 4 | (33.3%) | 6 | (28.6%) |  | 3 | (25.0%) | 8 | (44.4%) |  |
 Female | 8 | (66.7%) | 15 | (71.4%) | 1.000 | 9 | (75.0%) | 10 | (55.6%) | 0.442 |
Smoking history, n (%) | ||||||||||
 Never | 9 | (75.0%) | 15 | (71.4%) |  | 9 | (75.0%) | 10 | (55.6%) |  |
 Former/Current | 3 | (25.0%) | 6 | (28.6%) | 1.000 | 3 | (25.0%) | 8 | (44.4%) | 0.442 |
ECOG performance status, n (%) | ||||||||||
 0–1 | 10 | (83.3%) | 20 | (95.2%) |  | 8 | (66.7%) | 15 | (83.3%) |  |
 2–3 | 2 | (16.7%) | 1 | (4.8%) | 0.538 | 4 | (33.3%) | 3 | (16.7%) | 0.392 |
Histology, n (%) | ||||||||||
 Adenocarcinoma | 11 | (91.7%) | 19 | (90.5%) |  | 12 | (100.0%) | 18 | (100.0%) |  |
 Squamous cell carcinoma | 1 | (8.3%) | 0 | (0.0%) |  | 0 | (0.0%) | 0 | (0.0%) |  |
 Other | 0 | (0.0%) | 2 | (9.5%) | 0.279 | 0 | (0.0%) | 0 | (0.0%) | NA |
Clinical stage, n (%) | ||||||||||
 III | 0 | (0.0%) | 1 | (4.8%) |  | 0 | (0.0%) | 0 | (0.0%) |  |
 IV | 12 | (100.0%) | 15 | (71.4%) |  | 10 | (83.3%) | 15 | (83.3%) |  |
 Recurrence | 0 | (0.0%) | 5 | (23.8%) | 0.133 | 2 | (16.7%) | 3 | (16.7%) | 1.000 |
Metastases, n (%) | ||||||||||
 Brain | 7 | (58.3%) | 11 | (52.4%) | 1.000 | 6 | (50.0%) | 12 | (66.7%) | 0.458 |
 Bone | 4 | (33.3%) | 11 | (52.4%) | 0.469 | 6 | (50.0%) | 3 | (16.7%) | 0.102 |
 Liver | 2 | (16.7%) | 1 | (4.8%) | 0.538 | 3 | (25.0%) | 1 | (5.6%) | 0.274 |
EGFR mutation status, n (%) | ||||||||||
 Exon 19 deletion | 7 | (58.3%) | 10 | (47.6%) |  | 6 | (50.0%) | 7 | (38.9%) |  |
 L858R | 5 | (41.7%) | 10 | (47.6%) |  | 5 | (41.7%) | 11 | (61.1%) |  |
 Other | 0 | (0.0%) | 1 | (4.8%) | 0.825 | 1 | (8.3%) | 0 | (0.0%) | 0.351 |
Prior anticancer drug treatment, n (%) | ||||||||||
 None | 11 | (91.7%) | 19 | (90.5%) | 1.000 | 0 | (0.0%) | 0 | (0.0%) | NA |
 EGFR-TKI | 0 | (0.0%) | 1 | (4.8%) | 1.000 | 12 | (100.0%) | 18 | (100.0%) | NA |
 Chemotherapy | 3 | (25.0%) | 2 | (9.5%) | 0.233 | 7 | (58,3%) | 9 | (55.6%) | 0.722 |